OBJECTIVE: To describe the safety and tolerability of zidovudine, lamivudine, and efavirenz in a low-income setting. DESIGN: We conducted a prospective cohort study in a workplace HAART programme in South Africa, which uses a first-line regimen of efavirenz, zidovudine, and lamivudine and provides routine clinical and laboratory monitoring 6-monthly pre-HAART and at 2, 6, 12, 24, 36, 48 weeks during HAART. METHODS: We assessed the incidence of specified clinical and laboratory events (AIDS Clinical Trials Group grade 3 or higher) and associated regimen changes, hospitalizations, and deaths one year before HAART initiation and one year on-HAART using person-year analysis. RESULTS: Between November 2002 and October 2005, 853 subjects (98% male, median age 40 years, and median CD4 cell count at HAART initiation 186 cells/mul) met enrollment criteria. The incidence of events on-HAART was higher than pre-HAART for neutropenia and nausea/vomiting. Dizziness was common early after HAART initiation (not evaluated pre-HAART). Of those with neutropenia, 88% had no apparent clinical consequences. The incidence of anemia, hepatotoxicity, peripheral neuropathy, and rash was similar or higher pre-HAART than on-HAART. Mean hemoglobin rose during the time on-HAART and was higher at 24 and 48 weeks than at baseline (P < 0.001). DISCUSSION: This regimen was well tolerated with a short-term increase in neutropenia, nausea, and probably neurocerebellar events. Most significantly, in contrast to reports from high-income countries, we observed a long-term improvement in the hemoglobin concentration.
OBJECTIVE: To describe the safety and tolerability of zidovudine, lamivudine, and efavirenz in a low-income setting. DESIGN: We conducted a prospective cohort study in a workplace HAART programme in South Africa, which uses a first-line regimen of efavirenz, zidovudine, and lamivudine and provides routine clinical and laboratory monitoring 6-monthly pre-HAART and at 2, 6, 12, 24, 36, 48 weeks during HAART. METHODS: We assessed the incidence of specified clinical and laboratory events (AIDS Clinical Trials Group grade 3 or higher) and associated regimen changes, hospitalizations, and deaths one year before HAART initiation and one year on-HAART using person-year analysis. RESULTS: Between November 2002 and October 2005, 853 subjects (98% male, median age 40 years, and median CD4 cell count at HAART initiation 186 cells/mul) met enrollment criteria. The incidence of events on-HAART was higher than pre-HAART for neutropenia and nausea/vomiting. Dizziness was common early after HAART initiation (not evaluated pre-HAART). Of those with neutropenia, 88% had no apparent clinical consequences. The incidence of anemia, hepatotoxicity, peripheral neuropathy, and rash was similar or higher pre-HAART than on-HAART. Mean hemoglobin rose during the time on-HAART and was higher at 24 and 48 weeks than at baseline (P < 0.001). DISCUSSION: This regimen was well tolerated with a short-term increase in neutropenia, nausea, and probably neurocerebellar events. Most significantly, in contrast to reports from high-income countries, we observed a long-term improvement in the hemoglobin concentration.
Authors: Eric S Lugada; Jonathan Mermin; Frank Kaharuza; Elling Ulvestad; Willy Were; Nina Langeland; Birgitta Asjo; Sam Malamba; Robert Downing Journal: Clin Diagn Lab Immunol Date: 2004-01
Authors: K E Squires; R Gulick; P Tebas; J Santana; V Mulanovich; R Clark; B Yangco; S I Marlowe; D Wright; C Cohen; T Cooley; J Mauney; K Uffelman; N Schoellkopf; R Grosso; M Stevens Journal: AIDS Date: 2000-07-28 Impact factor: 4.177
Authors: Emmanuel O Idigbe; Taiwo A Adewole; Geoffrey Eisen; Phyllis Kanki; Nkiru N Odunukwe; Dan I Onwujekwe; Rosemary A Audu; Idowu D Araoyinbo; Joseph I Onyewuche; Oluwamuyiwa B Salu; John A Adedoyin; Adesola Z Musa Journal: J Acquir Immune Defic Syndr Date: 2005-09-01 Impact factor: 3.731
Authors: Kiros Berhane; Roksana Karim; Mardge H Cohen; Lena Masri-Lavine; Mary Young; Kathryn Anastos; Michael Augenbraun; D Heather Watts; Alexandra M Levine Journal: J Acquir Immune Defic Syndr Date: 2004-10-01 Impact factor: 3.731
Authors: Veronica Mulenga; Deborah Ford; A Sarah Walker; Darlington Mwenya; James Mwansa; Frederick Sinyinza; Kennedy Lishimpi; Andrew Nunn; Stephen Gillespie; Ali Zumla; Chifumbe Chintu; Diana M Gibb Journal: AIDS Date: 2007-01-02 Impact factor: 4.177
Authors: Ebrahim Variava; Farai R Sigauke; Jennifer Norman; Modiehi Rakgokong; Petudzai Muchichwa; Andre Mochan; Gary Maartens; Neil A Martinson Journal: J Acquir Immune Defic Syndr Date: 2017-08-15 Impact factor: 3.731
Authors: Hermann Bussmann; C William Wester; Ndwapi Ndwapi; Nicolas Grundmann; Tendani Gaolathe; John Puvimanasinghe; Ava Avalos; Madisa Mine; Khumo Seipone; Max Essex; Victor Degruttola; Richard G Marlink Journal: AIDS Date: 2008-11-12 Impact factor: 4.177
Authors: Charlotte Huet; Abdoulaye Ouedraogo; Issouf Konaté; Isidore Traore; François Rouet; Antoinette Kaboré; Anselme Sanon; Philippe Mayaud; Philippe Van de Perre; Nicolas Nagot Journal: BMC Public Health Date: 2011-09-14 Impact factor: 3.295